Status: Recruiting
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
Participants needed: 25
Trial details
Phase: Phase 1, Phase 2Age: 3+Biological sex: AllType: InterventionalSponsor: Fundación de investigación HMUpdated: Jun 4, 2026Locations: 1
Eligibility criteria
18 months - 18 years of age at the time of the initial diagnosis. [+22]
Previous significant drug-induced hepatitis toxicity experienced in the past tha... [+7]